{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 42,
        "end": 48
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 107,
        "end": 111
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 101,
        "end": 111
      }
    },
    {
      "id": "T5",
      "obj": "Chemical",
      "span": {
        "begin": 117,
        "end": 133
      }
    },
    {
      "id": "T6",
      "obj": "Chemical",
      "span": {
        "begin": 136,
        "end": 140
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 263,
        "end": 267
      }
    },
    {
      "id": "T8",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 279,
        "end": 283
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "11016647_4",
  "text": "One future approach to treatment of these tumors may rely on concurrent pharmacological depletion of tumor MGMT with O6-benzylguanine ( 6-BG ) and protection of sensitive tissues , such as hematopoietic stem and progenitor cells , using genetic modification with 6-BG -resistant MGMT mutants ."
}
